Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas
In trials involving thousands of adults with obesity or overweight, 4% to 5% of those taking Zepbound (5 mg, 10 mg, 15 mg) reported hair loss, compared to 1% in the placebo group
In early Phase 2 trials, participants lost up to approximately 24% of their body weight over 48 weeks at higher doses
Read our step-by-step guide
For a 50-year-old female with obesity, type 2 diabetes, and hypertension who is currently taking tirzepatide (Mounjaro) 12.5 mg weekly, phentermine 37.5 mg daily, losartan 50 mg, and spironolactone 50 mg, is it appropriate and safe to increase tirzepatide to 15 mg, continue phentermine for another month, and maintain her current antihypertensive regimen?